ImmunoTargets and Therapy
Scope & Guideline
Pioneering Discoveries in Immunotherapy
Introduction
Aims and Scopes
- Immunotherapy and Cancer Treatment:
The journal focuses extensively on various immunotherapeutic approaches, including immune checkpoint inhibitors, CAR-T cell therapies, and novel immunotherapies for different types of cancers such as non-small cell lung cancer, hepatocellular carcinoma, and multiple myeloma. - Autoimmunity and Inflammatory Diseases:
Research on the pathophysiology and treatment strategies for autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and eosinophilic esophagitis, is a significant scope of the journal. - Infectious Diseases and Immune Response:
The journal publishes studies on the immune response to infectious diseases, including tuberculosis and viral infections, highlighting the role of immune targets in treatment and prevention. - Emerging Biomarkers and Therapeutic Targets:
The identification and characterization of biomarkers and therapeutic targets across various diseases are central to the journal's mission, providing insights into personalized medicine and targeted therapies. - Research Methodologies in Immunology:
The journal supports diverse research methodologies, including clinical trials, retrospective studies, single-cell transcriptomics, and bioinformatics, to advance the understanding of immune mechanisms and therapeutic strategies.
Trending and Emerging
- Combination Therapies in Cancer Treatment:
There is a growing trend towards exploring combination therapies, particularly those involving immune checkpoint inhibitors and targeted therapies, which are increasingly recognized for their potential to enhance treatment efficacy. - Personalized Medicine and Biomarker Discovery:
Emerging themes include the identification of biomarkers that can predict treatment response, facilitating a move towards personalized medicine in immunotherapy, particularly in oncology. - Research on the Microbiome and Immune Interactions:
Studies exploring the relationship between the microbiome and immune responses are gaining traction, indicating a new frontier in understanding how microbiota can influence immunotherapy outcomes. - Innovative Approaches to Autoimmune Diseases:
The journal is increasingly publishing research on novel approaches to treating autoimmune diseases, including the use of biologics and targeted therapies that address specific immune pathways. - Advances in Gene Therapy and Immune Modulation:
Gene therapy strategies, particularly those aimed at immune modulation, are emerging as a significant focus, reflecting advancements in genetic engineering and its applications in immunotherapy.
Declining or Waning
- Traditional Pharmacotherapy for Autoimmune Diseases:
There is a noticeable decrease in publications focusing solely on traditional pharmacological treatments for autoimmune diseases, as the field shifts towards more innovative immunotherapy approaches. - Basic Immunology without Therapeutic Context:
The journal has seen a decline in studies that address basic immunological concepts without direct application to therapeutic interventions, reflecting a preference for research that links basic science to clinical outcomes. - Generalized Discussions on Allergies:
Research related to generalized allergy discussions, such as those not tied to specific therapeutic targets or novel treatments, appears to be waning, as the focus has shifted towards targeted immunotherapies. - Longitudinal Studies in Rare Diseases:
There is a reduced emphasis on longitudinal studies in rare autoimmune diseases, as the journal seems to prioritize studies with broader implications or more common conditions. - Generic Reviews of Established Treatments:
The frequency of generic reviews on established treatments without new insights or advances has decreased, as the journal encourages more innovative and research-driven articles.
Similar Journals
Immunotherapy
Shaping the Landscape of Immune Response and TreatmentImmunotherapy, published by Future Medicine Ltd, is a leading journal focused on the evolving field of immunotherapy within the realms of immunology, oncology, and allergy. With an ISSN of 1750-743X and an E-ISSN of 1750-7448, this academic journal has been at the forefront of groundbreaking research since 2009, and continues to illuminating insights in a landscape critical for the development of innovative therapeutic strategies through 2024. Positioned within Q2 and Q3 quartiles in various relevant categories, the journal ranks commendably in Scopus metrics, exhibiting robust engagement and relevance in Oncology and Immunology. It serves as an essential resource for researchers, clinicians, and students eager to stay abreast of advancements in immunotherapy, while also providing an open platform for sharing impactful studies. By disseminating high-quality research, Immunotherapy fosters a global dialogue among professionals and contributes significantly to the scientific community's collective knowledge on the increasing role of immune-based therapies in disease management.
GENES AND IMMUNITY
Advancing the Frontiers of Genetics and ImmunologyGENES AND IMMUNITY, published by SpringerNature, is a leading scholarly journal dedicated to advancing the field of genetics and immunology. With an impressive impact factor and a distinguished ranking in the Q1 quartile of both Genetics and Immunology disciplines for 2023, this journal serves as a pivotal platform for researchers and professionals looking to explore the intricate relationships between genetic factors and immune responses. Established in 1999 and continuously published until 2024, it features high-quality peer-reviewed research articles, reviews, and commentary that address critical issues and recent advancements in the field. The journal adheres to rigorous academic standards, evidenced by its strong Scopus rankings, making it a valuable resource for students, researchers, and practitioners alike who are seeking to deepen their understanding of genetics' role in immunity. For those looking to keep abreast of cutting-edge insights, GENES AND IMMUNITY is an essential read.
HUMAN IMMUNOLOGY
Advancing the Frontiers of Immune ResearchHUMAN IMMUNOLOGY, published by Elsevier Science Inc, serves as a critical platform for disseminating research in the fields of immunology and allergy, as well as various aspects of miscellaneous medicine since its inception in 1980. With an ISSN of 0198-8859 and E-ISSN 1879-1166, this journal is pivotal for researchers and practitioners looking to advance their understanding of human immune responses and related conditions. The journal currently holds a respectable position within its field, as highlighted by its 2023 Scopus ranks—#114/233 in Immunology and Allergy and #132/236 in Immunology and Microbiology. Moreover, it maintains a Q2 quartile ranking in both Immunology and Allergy and miscellaneous Medicine, underscoring its influence and reach within the scientific community. Although it does not currently offer Open Access options, HUMAN IMMUNOLOGY remains dedicated to providing valuable insights and fostering academic discourse within its discipline, characterized by a rigorous peer-review process and a focus on innovative research trajectories.
Immunological Medicine
Exploring the Frontiers of Immune HealthImmunological Medicine, published by Taylor & Francis Ltd, is an esteemed open-access journal that has made significant strides in the field of immunology since its establishment in 2018. With an E-ISSN of 2578-5826, the journal has quickly gained recognition for its contribution to advancing immunological research, evidenced by its impressive ranking in the Q2 quartile for both immunology and allergy. Positioned in the United Kingdom, it offers a platform for publishing high-quality original research, reviews, and case studies that delve into the complex interactions of the immune system and its implications for human health. The journal serves as a vital resource for researchers, professionals, and students engaged in the burgeoning fields of immunology, providing open access to a wide audience and fostering collaboration and innovation. With a current Scopus ranking of #81 out of 233 in Immunology and Allergy and #97 out of 236 in Immunology and Microbiology, the journal aims to enhance the visibility and impact of cutting-edge research by bridging the gap between academia and clinical practice.
Immunity
Pioneering research in immunity and infectious diseases.Immunity is a premier journal published by CELL PRESS that has positioned itself at the forefront of immunological research since its inception in 1994. With its ISSN 1074-7613 and E-ISSN 1097-4180, this prestigious journal is recognized for its significant contribution to the fields of Immunology, Allergy, and Infectious Diseases, consistently achieving a Q1 ranking in these categories as per 2023 metrics. The journal is highly esteemed within the academic community, holding impressive Scopus rankings—4th out of 344 in Infectious Diseases and 3rd in both Immunology and Immunology and Allergy—placing it in the 98th percentile. Although not an Open Access journal, it provides critical insights and research developments that empower researchers, healthcare professionals, and students alike. With a commitment to advancing scientific knowledge, Immunity is crucial for those interested in understanding immune responses and their implications for health and disease.
Science Immunology
Championing Open Access to Immunological BreakthroughsScience Immunology, published by the American Association for the Advancement of Science, is a leading journal in the field of immunology, recognized for its significant impact and rigor in advancing our understanding of immune responses and complex diseases. With an impressive impact factor that places it in the Q1 category of both immunology and allergy, as well as miscellaneous medicine, this journal is ranked #7 and #8 in their respective Scopus categories, reflecting its high-quality research output. Since its inception in 2016, Science Immunology has been at the forefront of interdisciplinary immunological research, fostering crucial insights that link immunology with pressing health challenges. The journal is committed to providing open access to its content, ensuring that groundbreaking findings are accessible to a global audience of researchers, professionals, and students. Its anthology not only addresses fundamental immunological mechanisms but also enhances the dialogue on translational applications and therapeutic interventions, solidifying its position as an essential resource within the scientific community.
GENE THERAPY
Transforming Healthcare Through Genetic InsightsGENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.
Immunity Inflammation and Disease
Connecting researchers to foster collaboration in immune science.Immunity, Inflammation and Disease is a premier open-access journal published by WILEY, dedicated to advancing the field of immunology and allergy. Launched in 2013, this journal has established itself as a significant platform for researchers and professionals to disseminate high-quality research findings and innovative insights that address critical issues in immune responses and inflammatory diseases. With an impact factor that reflects its growing influence and a current ranking in Q3 for Immunology and Q2 for Immunology and Allergy, this journal serves a diverse audience keen on exploring cutting-edge developments. Researchers are encouraged to submit their work to share their findings with a global reach, foster collaboration, and enhance the understanding of immune mechanisms and therapeutic strategies. Accessible since its inception, Immunity, Inflammation and Disease is committed to open science, ensuring that vital research is freely available for the advancement of knowledge within the academic community and beyond.
Journal of Immunology Research
Unlocking Immune Mechanisms: Where Discovery Meets AccessibilityJournal of Immunology Research, published by HINDAWI LTD, stands as a pivotal open-access journal in the realm of immunology, with a particular emphasis on advancing knowledge in both fundamental and applied aspects of the field. Since its inception in 1990, the journal has committed to the dissemination of high-quality research, earning a respectable impact factor that reflects its significance. Based in Egypt, it provides a platform for researchers from around the world, showcasing innovative studies and reviews that contribute to the understanding of immune system mechanisms. Its 2023 rankings place it in the Q2 category for Immunology and Allergy, and Q1 in the broader category of Medicine (miscellaneous), indicating a strong reputation among its peers. Through its open-access model, the journal promotes wide accessibility of cutting-edge research, catering to researchers, professionals, and students alike. With ambitions that converge through 2024, the Journal of Immunology Research continues to be an essential resource for those seeking to explore the forefront of immunological science.
JOURNAL OF IMMUNOTHERAPY
Exploring Innovative Pathways in ImmunotherapyJOURNAL OF IMMUNOTHERAPY, published by Lippincott Williams & Wilkins, is a premier journal dedicated to advancing the field of immunotherapy, a vital aspect of contemporary cancer research and treatment. With an ISSN of 1524-9557 and an E-ISSN of 1537-4513, this esteemed journal has been disseminating cutting-edge research since 1991 and continues to thrive with a convergence of knowledge leading into 2024. Recognized in the top Q2 quartile for fields such as Cancer Research, Immunology, and Allergy, as well as achieving a Q1 ranking in Pharmacology, the journal serves as a critical resource for researchers, clinicians, and students alike. Its robust impact is reflected in its competitive Scopus rankings across various categories, where it holds significant percentile standings. Highly regarded in the academic community for its rigor, the JOURNAL OF IMMUNOTHERAPY aims to provide a platform for innovative ideas, clinical findings, and experimental research that propels the science of immunotherapy forward. Although it does not offer open access, the journal ensures that its contents remain accessible and impactful for professionals in the field, fostering collaboration and knowledge exchange in an era where immunotherapy holds the promise for breakthroughs in patient care.